## Claims

## 1. Compounds of the general Formula

$$R^{1} \xrightarrow[R^{2}]{R^{4}} \xrightarrow[R^{5}]{Q} \xrightarrow[R^{6}]{R^{7}} \xrightarrow[R^{8}]{R^{10}} \xrightarrow{X} \xrightarrow{R^{10}} \xrightarrow{X} \xrightarrow{R^{11}} \xrightarrow{Q} \qquad (II)$$

Wherein

A represents an optionally substituted 5- or 6-membered heteroaryl ring;

X is O, S or a group of Formula NR<sup>13</sup> or CR<sup>14</sup>R<sup>15</sup>;

Y is O, S or a group of Formula NR16 and

Residues R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup> and R<sup>16</sup> are independently of each other H, alkyl, alkenyl, alkinyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocyloalykl, aralkyl or heteraralkyl, or two residues constitute part of a cycloalkyl or heterocycloakyl,

or a pharmacologically acceptable salt, solvate, hydrate or a pharmacologically acceptable formulation thereof;

wherein compounds of Formula (I) are excluded,

$$\begin{array}{c|c} & & & & \\ & & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

wherein R' is H, alkyl, alkenyl, aryl, or heteroaryl and R'' is H, OH, alkyl, aryl or heteroaryl.

2. Compounds of Claim 1, wherein A has the following structure:

- 3. Compounds of Claim 1 or 2, wherein X is a CH2 group.
- 4. Compounds of Claim 1 to 3, wherein Y is O.
- 5. Compounds according to anyone of Claim 1 to 4, wherein  $R^1$  is a  $C_1\text{--}C_4$  alkyl group.
- 6. Compounds according to anyone of Claims 1 to 5, wherein,  $R^2$  and  $R^3$  together constitute a group of Formula  $(CH_2)_n$  wherein n is 2, 3, 4 or 5.
- 7. Compounds according to Claims 1 to 6, wherein R4 is H or methyl.
- 8. Compounds according to Claims 1 to 7, wherein  $R^5$  is H.
- 9. Compounds according to Claims 1 to 8, wherein  $R^6$  is  $C_1-C_6$  alkyl,  $C_3-C_6$  cycolalkyl or  $C_4-C_7$  alkylcycloalkyl.
- 10. Compounds according to Claims 1 to 9, wherein  $\mathbb{R}^7$  is H or methyl.
- 11. Compounds according to Claims 1 to 10, wherein  $R^8$  is a group of Formula  $CH_2OCOR^{17}$ , wherein  $R^{17}$  is  $C_1-C_7$  alkyl or  $C_1-C_6$  alkenyl.

- 12. Compounds according to Claims 1 to 11, wherein  $R^9$  is  $C_1-C_6$  alkyl.
- 13. Compounds according to Claims 1 to 12, wherein  $\mathbb{R}^{10}$  is H or methyl.
- 14. Compounds according to Claims 1 to 13, wherein  $\mathbb{R}^{11}$  is H or a group of Formula  $(C=0)-(C_{1-4})$  alkyl.
- 15. Compounds according to Claims 1 to 14, wherein  $R^{12}$  is a group of Formula  $NR^{18}R^{19}$ , wherein  $R^{18}$  is H or methyl and wherein  $R^{19}$  is aralkyl or heteroaralkyl.
- 16. A pharmaceutical composition containing a compound according to Claims 1 to 15 and optionally carriers and/or adjuvants.
- 17. Use of compounds or a pharmaceutical composition according to Claims

  1 to 16 for the treatment of tumors, immune diseases, autoimmune

  diseases, inflammatory diseases and rheumatoid arthritis as well as

  surface modifications of plastic or metal implants.
- 18. Use of a compound or a pharmaceutical composition according to Claims
  1 to 16 for the treatment of cancer diseases.

The present invention relates to novel tubulysin analogs and its use for the treatment of cancer diseases.